<DOC>
	<DOCNO>NCT00242580</DOCNO>
	<brief_summary>To evaluate safety efficacy combination treatment wet age-related macular degeneration . The combination treatment consist verteporfin photodynamic therapy either triamcinolone acetonide pegaptanib add intravitreal injection .</brief_summary>
	<brief_title>A Safety Efficacy Study Comparing Combination Treatments Verteporfin Therapy Plus One Two Different Doses Intravitreal Triamcinolone Acetonide Verteporfin Therapy Plus Intravitreal Pegaptanib</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>age &gt; 50 type untreated subfoveal choroidal neovascularization secondary AMD lesion size &lt; 5400 micron great linear dimension ( GLD ) history prior photodynamic therapy , external beam radiation , subfoveal focal laser photocoagulation , submacular surgery , transpupillary thermotherapy know allergy verteporfin , triamcinolone pegaptanib receive prior treatment Macugen , antiangiogenic compound investigational treatment ( e.g . Ruboxistaurin , Lucentis [ ranibizumab ] , Retaane [ anecortave acetate ] , squalamine , siRNA , VEGFTrap etc . ) neovascular AMD presence fibrosis , hemorrhage , pigment epithelial detachment , tear ( tip ) retinal pigment epithelium hypoflourescent lesion obscure great 50 % CNV lesion previous par plana vitrectomy study eye Other protocolspecified inclusion/exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AMD</keyword>
	<keyword>age-related macular degeneration</keyword>
	<keyword>choroidal neovascularization</keyword>
</DOC>